13-Valent Pneumococcal Conjugate Vaccine

Nancy M. Bennett, MD, MS
Pneumococcal Vaccines Work Group Chair
Advisory Committee on Immunization Practices
October 23, 2013



Pneumococcal Vaccines Work Group

ACIP members

Nancy Bennett (Chair)

Arthur Reingold

Jeffrey Duchin

Allison Kempe

Lorry Rubin

Ex Officio members

Lucia Lee (FDA)

Tina Mongeau (FDA)

Designated Federal Officer (CDC/NCIRD)

Tamara Pilishvili

Liaison representatives and consultants

Rick Zimmerman (AAFP)

William Schaffner (NFID)

Caroline Quach (NACI)

Mark Sawyer (AAP, PIDS)

Jane Zucker (AIM)

Monica Farley (VA)

Kathy Neuzil (IDSA)

Anthony Brenneman (AAPA)

Sandra Fryhofer (ACP, AMA)

Pneumococcal Vaccines Work Group: Terms of Reference


 Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines

- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

Focus of today's session

- 13-valent pneumococcal conjugate vaccine (PCV13)
- Routine infant immunization schedule for PCV13

Pneumococcal WG activities 2010-2013



IC = with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants

Context for today's session

- PCVs used in the U.S. for past 12 years on 4-dose schedule (at 2, 4, 6, and 12 through 15 months of age)
- PCV7 use led to reductions in otitis media in children and invasive pneumococcal disease (IPD) and pneumonia in children and adults
- Evidence emerging supporting 3-dose PCV schedule
 - RCTs evaluating efficacy and immunogenicity
 - Observational studies evaluating impact (at least 34 high or upper-middle income countries have introduced PCV13 or PCV10 with 3 doses)

Objective for today's session

- Information only session; no specific recommendations will be presented
- Review evidence and discuss considerations for including a 3-dose PCV13 schedule for infants
- Questions for the committee
 - Is the evidence adequate to consider including a 3dose PCV13 schedule for infants?
 - If not, what additional data or information would be required?

Today's presentations

Update on PCV13 direct and indirect effects & vaccine effectiveness	Matt Moore
Discussion/Q&A	
Reduced dose schedules of PCV13 for children: review of evidence	Tamara Pilishvili
Discussion/Q&A	
Cost-effectiveness of PCV13 reduced dose schedules	Charles Stoecker
Discussion/Q&A	